AbbVie lifts its quarterly dividend 5.5% to $1.73 a share
As seen on the 24/7 Wall St. homepage on October 15, 2026.
A 5.5% raise to $1.73 a quarter says management sees cash flow holding up even as Humira fades. Buy after Thursday and you miss this payout; the indicated yield sits at 2.44%.
Continue ReadingShow less
AbbVie has now raised its dividend for 13 consecutive years, with the latest 5.5% increase pushing the quarterly payment to $1.73 per share. That pace signals management is confident enough in cash generation to keep rewarding shareholders above the rate of inflation.
The timing matters because Humira, once the world's best-selling drug, has faced biosimilar competition that has steadily eroded its contribution to AbbVie's revenue. Raising the dividend into that headwind is a deliberate statement from the board that the rest of the portfolio, including newer immunology and oncology products, is picking up enough slack to keep the payout growing.
The ex-dividend date is October 15, 2026, so investors who buy shares on or after that date will not receive this quarterly payment. Holders collect an indicated yield of 2.44% on the new rate.
Thirteen years of unbroken dividend growth places AbbVie firmly among companies that treat the payout as a priority. Management has held that record through a major patent cliff, the kind of stress test that separates durable income stocks from ones that cut when conditions get difficult.
Sources
Mentioned: ABBV